KalVista Pharmaceuticals: Our Verdict [Seeking Alpha]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Seeking Alpha
KalVista Pharmaceuticals: Our Verdict Summary Clinical-stage biopharma KalVista Pharmaceuticals has lost approximately 40% of its value since early April as it entered a news vacuum. That should change with three data readouts anticipated over the next few months for its portfolio of plasma kallikrein inhibitors. A Merck option agreement and recent insider buying merited further analysis. A full investment analysis appears in the paragraphs below. Your fear is 100% dependent on you for its survival Today, we look at a small developmental concern that has not has a lot of news flow in recent months and whose stock is down some 40% from recent highs. However, several key readouts through year end could change sentiment on the shares. Our in-depth look at this name follows below. Company Overview KalVista Pharmaceuticals, Inc. ( KALV PKal is a serine protease enzyme that is a key early mediator of inflammation and edema. The inflammatory effects of PKal are regulated by an inhibitor prot
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.MarketBeat
- KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]Yahoo! Finance
- KalVista Appoints Jeb Ledell as Chief Operating OfficerBusiness Wire
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
KALV
Earnings
- 12/5/24 - Beat
KALV
Sec Filings
- 12/16/24 - Form 8-K
- 12/9/24 - Form 4
- 12/5/24 - Form 8-K
- KALV's page on the SEC website